ConductScience.org, home
Study to Compare the Efficacy and Safety of Enzyme Replacement Therapies Avalglucosidase Alfa and Alglucosidase Alfa Administered Every Other Week in Patients With Late-onset Pompe Disease Who Have Not Been Previously Treated for Pompe Disease
API referenceFor AI assistants

Trial · NCT02782741

Participant flow24

How many started, completed or left each group, period by period.

1 to 20 of 24

Download this page as JSON
PeriodMilestoneGroupParticipantsUnits counted
Blinded Treatment Period: up to Week 49STARTEDAvalglucosidase Alfa51
Blinded Treatment Period: up to Week 49STARTEDAlglucosidase Alfa in PAP Then Avalglucosidase Alfa in Open-label49
Blinded Treatment Period: up to Week 49STARTEDAvalglucosidase Alfa in Open-label Only0
Blinded Treatment Period: up to Week 49Safety PopulationAvalglucosidase Alfa51
Blinded Treatment Period: up to Week 49Safety PopulationAlglucosidase Alfa in PAP Then Avalglucosidase Alfa in Open-label49
Blinded Treatment Period: up to Week 49Safety PopulationAvalglucosidase Alfa in Open-label Only0
Blinded Treatment Period: up to Week 49COMPLETEDAvalglucosidase Alfa51
Blinded Treatment Period: up to Week 49COMPLETEDAlglucosidase Alfa in PAP Then Avalglucosidase Alfa in Open-label44
Blinded Treatment Period: up to Week 49COMPLETEDAvalglucosidase Alfa in Open-label Only0
Blinded Treatment Period: up to Week 49NOT COMPLETEDAvalglucosidase Alfa0
Blinded Treatment Period: up to Week 49NOT COMPLETEDAlglucosidase Alfa in PAP Then Avalglucosidase Alfa in Open-label5
Blinded Treatment Period: up to Week 49NOT COMPLETEDAvalglucosidase Alfa in Open-label Only0
Open-label Long-term: Week 50 to 289STARTEDAvalglucosidase Alfa51
Open-label Long-term: Week 50 to 289STARTEDAlglucosidase Alfa in PAP Then Avalglucosidase Alfa in Open-label44
Open-label Long-term: Week 50 to 289STARTEDAvalglucosidase Alfa in Open-label Only1
Open-label Long-term: Week 50 to 289Safety PopulationAvalglucosidase Alfa51
Open-label Long-term: Week 50 to 289Safety PopulationAlglucosidase Alfa in PAP Then Avalglucosidase Alfa in Open-label44
Open-label Long-term: Week 50 to 289Safety PopulationAvalglucosidase Alfa in Open-label Only1
Open-label Long-term: Week 50 to 289COMPLETEDAvalglucosidase Alfa44
Open-label Long-term: Week 50 to 289COMPLETEDAlglucosidase Alfa in PAP Then Avalglucosidase Alfa in Open-label36

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Next page

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT02782741/flow

API referenceFor AI assistants